Clinical Trials Logo

Oral Lichen Planus clinical trials

View clinical trials related to Oral Lichen Planus.

Filter by:

NCT ID: NCT06078579 Recruiting - Oral Lichen Planus Clinical Trials

Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.

Start date: December 30, 2023
Phase:
Study type: Observational

This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.

NCT ID: NCT06060301 Active, not recruiting - Oral Lichen Planus Clinical Trials

Topical Sulfasalazine and Oral Lichen Planus

Start date: March 1, 2023
Phase: Phase 3
Study type: Interventional

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown. Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.

NCT ID: NCT06042010 Completed - Oral Lichen Planus Clinical Trials

Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus

Start date: January 5, 2023
Phase: N/A
Study type: Interventional

Lichen Planus (LP) is a chronic mucocutaneous inflammatory disease and considered as T-cell mediated autoimmune disorder. Zinc is a potent antioxidant micronutrient that contributes to the proper functioning of the antioxidant defense system. In addition, this mineral protects cells against inflammation by oxidative stress, because it acts in the stabilization of cell membrane. It also maintains macrophage and neutrophil functions, natural killer cell activity, and complement activity. Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases and have the main function of proteolytic degradation of connective tissue matrix proteins. Zinc prevents (MMP-1) activation and inhibition of the T-cell accumulation in (OLP) through inhibiting of (MMP-9). Aim of the study: To evaluate and compare the efficacy of adding oral zinc supplementation 50 mg to 0.1%Triamcinolone orabase (TA)versus 0.1%Triamcinolone orabase alone on the healing of erosive OLP.

NCT ID: NCT06033105 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Deficiency as a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus

Start date: August 1, 2023
Phase:
Study type: Observational

To investigate the role of Vitamin D (VD) deficiency as a risk factor for the development and malignant transformation of Oral lichen planus (OLP) taking into consideration sex, dietary habits, sun exposure, socioeconomic status and psychological factors.

NCT ID: NCT05997173 Recruiting - Oral Lichen Planus Clinical Trials

The Regulatory Role of Immune Response in Oral Lichen Planus

Start date: September 7, 2020
Phase:
Study type: Observational

Oral lichen planus (OLP) is a common chronic inflammatory disease of Oral mucosa. The pathogenesis of OLP is not clear, and there is no effective method to cure it. In vitro, previous studies have shown that oral mucosal mesenchymal stem cell cells (MSCs) can secrete Ido, which is involved in the pathogenesis of OLP. It has been proved that mental disorders such as depression and anxiety play an important role in the pathogenesis and treatment of OLP. Mental stress factors can cause abnormal changes of inflammatory factors, leading to immune dysfunction, which is also one of the main causes of OLP. In this study, we integrated the advantages of stomatology, psychiatry, neurobiology and traditional Chinese medicine, focused on the clinical problems of mental disorders with oral mucosal comorbidity, and assessed the depressive and anxiety status of OLP patients, so as to improve the therapeutic effect of OLP.

NCT ID: NCT05973097 Recruiting - Oral Lichen Planus Clinical Trials

Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. It is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. The pathogenesis of OLP is still unclear, but it is believed to be a T-lymphocyte-mediated autoimmune disease. Currently, only symptomatic treatments are available, and there is no definitive cure. In this project, we plan to use TCM differentiation to categorize OLP patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for OLP. The implementation of this project will provide new insights into the clinical management of OLP, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.

NCT ID: NCT05942794 Recruiting - Oral Cancer Clinical Trials

Identification of Oral Lesions Through an Autofluorescence System

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The aim of the study will be to evaluate the efficacy of a tissue autofluorescence detection system as an aid to clinical screening in identifying lesions of the oral mucosa. The screening process will be performed by 3 clinicians with a different level of experience. Sensitivity and specificity tests will be conducted.

NCT ID: NCT05882864 Not yet recruiting - Oral Lichen Planus Clinical Trials

Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus With Immunohistochemical Analysis

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

1. Compare the clinical efficacy of topical ginger extract versus triamcinolone acetonide 0.1% for symptomatic oral lichen planus (Primary Objective). 2. Investigate using immunohistochemical analysis the effect of the two different treatment modalities on FasL expression in oral lichen planus lesions (Secondary Objective).

NCT ID: NCT05818618 Completed - Oral Lichen Planus Clinical Trials

Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus

Start date: March 12, 2020
Phase: N/A
Study type: Interventional

According to recent research, microRNAs (miRNAs) may function as early disease indicators and contribute to the severity of a number of precancerous and malignant oral disorders. The aim of the present study, through a double-blind randomized controlled trial design, is to analyze in the gingival crevicular fluid (GCF) as a non-invasive approach the impact of topical clobetasol on miRNAs expression in subjects affected by oral lichen planus (OLP).

NCT ID: NCT05730855 Completed - Oral Lichen Planus Clinical Trials

Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions

Start date: November 1, 2022
Phase:
Study type: Observational

The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.